Stockscreener 앱 받기
22.64
0.13%
0.03
시간 외 거래:
22.61
-0.03
-0.13%
전일 마감가:
$22.61
열려 있는:
$22.75
하루 거래량:
588.19K
Relative Volume:
0.77
시가총액:
$1.67B
수익:
$434.49M
순이익/손실:
$504.34M
주가수익비율:
3.7647
EPS:
6.0138
순현금흐름:
$181.97M
1주 성능:
-1.57%
1개월 성능:
+3.05%
6개월 성능:
+12.92%
1년 성능:
+5.60%
1일 변동 폭
$22.37
$22.86
1주일 범위
$22.33
$23.37
52주 변동 폭
$16.52
$25.14
Innoviva Inc Stock (INVA) Company Profile
명칭
Innoviva Inc
전화
(650) 238-9600
주소
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
22.64 | 1.65B | 434.49M | 504.34M | 181.97M | 6.0138 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 개시 | BTIG Research | Buy |
| 2025-09-30 | 개시 | Goldman | Sell |
| 2025-08-11 | 개시 | Oppenheimer | Outperform |
| 2025-07-14 | 개시 | H.C. Wainwright | Buy |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-07-20 | 개시 | Goldman | Neutral |
| 2017-11-20 | 개시 | Deutsche Bank | Hold |
모두보기
Innoviva Inc 주식(INVA)의 최신 뉴스
Responsive Playbooks and the INVA Inflection - Stock Traders Daily
INVA Q1 2026 Earnings: EPS Falls Far Short of Estimates, Stock DeclinesRevenue Per Share - newsline.com
Innoviva Inc. (INVA) Q1 2026 Earnings: Significant EPS Miss Despite Positive Stock ReactionQuarterly Earnings Report - newsline.com
Innoviva stock rises to $23.00 amid constructive trends and renewed buyer momentum - Traders Union
INVA Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; Stock Rises 0.94%Final Results - newsline.com
Innoviva (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary - Quartr
Understanding the Setup: (INVA) and Scalable Risk - Stock Traders Daily
Innoviva Board Shift And New Treatment Launch Create Valuation Question - Sahm
Innoviva, Inc. to Present at Investor Conferences - geneonline.com
Innoviva to Participate in Upcoming Investor Conferences - New Castle News
INVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $46 - GuruFocus
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More - AOL.com
Has Innoviva Successfully Pivoted Beyond its Royalty Roots - Kavout
INVA Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclineFull Year Guidance - The Legal Advocate
INVA Q1 2026 Earnings: EPS Miss Triggers 2% Stock DeclineDividend Cut Risk - The Legal Advocate
Innoviva (INVA) Holds Near Key Support on Light Volume as Biotech Sector Navigates UncertaintyBullish Pattern Stocks - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI), NeOnc Technologies Holdings, Inc. (NTHI) and Innoviva (INVA) - The Globe and Mail
Innoviva (INVA) Q1 2026 Earnings: EPS Misses Estimates by Over 112%, Stock DeclinesEarnings Call Highlights - newsline.com
INVA Reiterates by BTIG -- Price Target Maintained at $42 - GuruFocus
Innoviva Inc. (INVA) Gains Ground Amid Sector DynamicsPost-Earnings Moves - The Legal Advocate
INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals - ChartMill
The Technical Signals Behind (INVA) That Institutions Follow - Stock Traders Daily
INVA Q1 2026 Earnings: Significant EPS Miss Amid Lack of Revenue DisclosureOne-Time Loss Impact - Newser
INVA Q1 2026 Earnings: EPS Misses Estimates Despite Modest Stock GainOpen Signal Network - Newser
Innoviva (INVA) CFO adds ESPP shares and uses stock to pay taxes - Stock Titan
Innoviva (INVA) CEO logs ESPP share grant and tax withholding on Form 4 - Stock Titan
Innoviva (NASDAQ: INVA) CAO has shares withheld to cover tax obligations - Stock Titan
Innoviva (INVA) Q1 2026 Earnings Miss by Significant: Key TakeawaysHot Momentum Watchlist - Newser
Innoviva Appoints Josephine Linden to Strengthen Board Oversight - TipRanks
Innoviva Board Shakeup Puts Governance And Valuation In Focus - Sahm
Innoviva (INVA) director receives RSU and stock option grants as board compensation - Stock Titan
Innoviva (INVA) director Josephine Linden files Form 3 showing no share ownership - Stock Titan
Innoviva announces board changes and appoints Josephine Linden as director - Investing.com Nigeria
Innoviva (INVA) refreshes board as two directors resign, adds Josephine Linden - Stock Titan
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Sahm
Armata Pharmaceuticals (ARMP) Q1 2026: EPS -3.16 Misses Est. -0. - GuruFocus
Precision Trading with Innoviva Inc. (INVA) Risk Zones - Stock Traders Daily
Armata Pharmaceuticals (ARMP) now 82.7% owned by Innoviva after new loan - Stock Titan
Armata (NYSE: ARMP) loss, debt surge and Phase 3 bacteremia trial plan - Stock Titan
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Press Release: Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Moomoo
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress - Quantisnow
TradingKey - TradingKey
Why are smart money investors paying attention to Innoviva (INVA)? (Mini Rally) 2026-05-11Professional Trade Ideas - newser.com
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness? - Yahoo Finance
What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For Shareholders - simplywall.st
Innoviva Inc Emerges as Top Small Cap Value Stock with High Royalty Revenues - HarianBasis.co
Innoviva Inc (INVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):